| Joseph A. Ziegler |
Joseph A. Ziegler is currently serving as an Independent Director at Progressive Care, Inc. since 2021 and as the Chief Financial & Accounting Officer at TherapeuticsMD, Inc. since 2023. Previously, he held positions as Principal at Jarden Corp., Miami Subs Corp., Value Rent-A-Car, Inc., and Global Tower LLC. From 2009 to 2012, he served as the Chief Financial Officer at Proven Pharmaceuticals LLC. He also held the position of Chief Financial Officer at Encompass Onsite LLC. In 2021, he briefly served as the Chief Financial Officer at DAS Health Ventures LLC. Mr. Ziegler obtained his undergraduate degree and an MBA from Florida Atlantic University. |
| Marlan D. Walker |
Marlan D. Walker is currently the Chief Executive Officer at TherapeuticsMD, Inc. He previously worked as the Intellectual Property Counsel at Medicis Pharmaceutical Corp. from 2011 to 2012. Mr. Walker has an undergraduate degree and a graduate degree from Brigham Young University. He also holds a graduate degree from George Washington University Law School, which he obtained in 2005. Additionally, he has a graduate degree from Sandra Day O'Connor College of Law, which he received in 2004. |
| Bharat Warrier |
Bharat Warrier is currently the Chief Manufacturing Officer at TherapeuticsMD, Inc. He has a graduate degree from the University of Missouri-Kansas City and an undergraduate degree from Sri Ramachandra Institute of Higher Education & Research. |
| Tommy George Thompson |
Tommy George Thompson is currently the Chairman of EdLogics LLC, the Executive Chairman of TherapeuticsMD, Inc., the Chairman of HealthcarePays Network LLC, and a Director at Scilex, Inc., Healthpeak Properties, Inc., and other organizations. He has also served as the Chairman and Chief Executive Officer of Thompson Holdings, Inc., Chairman of AGA Medical Holdings, Inc., Chairman of CareView Communications, Inc., and Chairman of OptumServe Health Services, Inc., among other former positions. Dr. Thompson has an education background with undergraduate and graduate degrees from the University of Wisconsin. |
| C. Christine Miller |
C. Christine Miller is currently the Chief Operating Officer at Sirion Holdings, Inc. and the Chief Regulatory & Quality Officer at TherapeuticsMD, Inc. Her former positions include being an Associate Director-Regulatory Affairs at Bayer Corp. from 1991 to 1994, Global Vice President-Drug Regulatory Affairs at Bausch & Lomb, Inc. from 1994 to 2001, an Associate at AMAG Pharma USA, Inc. in 1986 and 1987, Vice President-Regulatory & Quality Assurance at Santarus, Inc. from 2001 to 2006, Senior Vice President-Drug Development at Sirion Therapeutics, Inc. from 2006 to 2010, and Chief Operating Officer at Rx Development Resources LLC from 2006 to 2010. She also worked as an Associate at Mallinckrodt Medical, Inc. (US) from 1987 to 1991. Dr. Miller is the President of Pharmareg Solutions Ltd. She holds a doctorate degree from the University of Nebraska. |
| Cooper C. Collins |
Cooper C. Collins is currently the Chief Executive Officer at Dominion Aesthetic Technologies, Inc. and Fortis BioPharma. He is also an Independent Director at TherapeuticsMD, Inc. and a Managing Partner & CIO at Magnasci Ventures. Previously, he held positions such as President, Chief Executive Officer & Director at Golf Trust of America, Inc., President & Chief Executive Officer at Pernix Therapeutics LLC, and Chief Executive Officer at Pernix Therapeutics, Inc. He has also served as a Director at Oncternal Oncology, Inc. and Chief Strategy Officer at Pernix Therapeutics Holdings, Inc. Mr. Collins completed his undergraduate degree and MBA at Nicholls State University. |
| Gail K. Naughton |
Gail K. Naughton is the founder of Advanced Tissue Sciences, Inc. (1991), Histogen, Inc. (2007), and Histogen, Inc. (2005). She is currently the Chairman at La Jolla Institute For Immunology, Executive Chairman at BiOHIP, Inc., Director at CEL-SCI Corp., Independent Director at TherapeuticsMD, Inc., Director at Octet Medical, Inc., Head-Regenerative Therapeutics & Commercialization at HippoFi, Inc., and Professor at City University of New York. Her former positions include Independent Director at C. R. Bard, Inc. (New Jersey) (2004-2017), Director at Kratos Technology & Training Solutions, Inc., Director at Celera Corp. (2008-2011), Director at DermTech Operations, Inc., Independent Director at Plus Therapeutics, Inc. (2014-2018), Director at City of Hope National Cancer Institute, Director at Centre For Commercialization of Regenerative Medicine, and Advisor at Proteus RM LLC (Venture Capital). Dr. Naughton has an MBA from the University of California, Los Angeles, an undergraduate degree from St. Francis College, and graduate and doctorate degrees from New York University School of Medicine. |
| Jules A. Müsing |
Jules A. Müsing is a businessperson who has been at the helm of 5 different companies is on the board of Delphi Digital, Inc. and TherapeuticsMD, Inc. In his past career he occupied the position of Director at ZyVersa Therapeutics, Inc., President for Pitman-Moore, Inc., Vice President-Licensing & Acquisitions at Johnson & Johnson and Managing Director at Janssen Farmaceutica Portugal Lda. (a subsidiary of Johnson & Johnson), Managing Director at Biotech Ortho SAS and President of EMD Serono, Inc.
Mr. Müsing received an undergraduate degree from the University of Antwerp and a graduate degree from Vrije Universiteit Brussel. |
